Meeting
2024 ASCO Gastrointestinal Cancers Symposium
De novo metastatic versus recurrent gastroesophageal cancer: A single-centre retrospective analysis.
Authors
Abdul Rehman Farooq
Princess Margaret Cancer Centre, Toronto, ON, Canada
Abdul Rehman Farooq , Zeynep Baskurt , Thais Baccili Cury Megid , Carly C. Barron , Marie-Philippe Saltiel , Xin Wang , Ronan Andrew McLaughlin , Ekaterina Kosyachkova , Yvonne Bach , Hiroko Aoyama , Raymond Woo-Jun Jang , Eric Xueyu Chen , Lucy Xiaolu Ma , Sangeetha Kalimuthu , Rebecca KS Wong , Aruz Mesci , Jonathan Yeung , Elliott Wakeam , Elena Elimova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 282)
DOI
10.1200/JCO.2024.42.3_suppl.282
Abstract #
282
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.
First Author: Heba Mohamed
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The distribution of human epidermal growth factor receptor 2 (HER2) expression and the efficacy and safety of treatments in HER2-expressing advanced or metastatic gastroesophageal cancer: A systematic literature review (SLR).
First Author: David Bing Zhen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase III study comparing 2-weekly docetaxel, cisplatin and 5-FU (bDCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer: JCOG1314 (MIRACLE).
First Author: Takahiro Tsushima